Study Description
This study is a multicenter observational study with a central registration system and all-case surveillance system without a control group.
Interventions
LUTATHERA
Eligibility Criteria
Inclusion Criteria:
All patients treated with this drug for the following indications during a certain post-marketing period
Indication: Somatostatin receptor-positive neuroendocrine tumor Patients who started to receive this drug before the contract for this study will also be included in the study population and it will be allowed to register them after the contract so that all patients who receive this drug will be included in this study. Patients treated with this drug for off-label indication will also be included in this study to register all patients received this drug.
Exclusion Criteria:
Not applicable
Study Location
Novartis Investigative Site
Recruiting
Kamakura-city,Kanagawa,247-8533,Japan
Novartis Investigative Site
Recruiting
Chiba,260-8717,Japan
Novartis Investigative Site
Recruiting
Suwa,Nagano,392-8510,Japan
Novartis Investigative Site
Recruiting
Kamogawa-City,Chiba,296-0041,Japan
Novartis Investigative Site
Recruiting
Chuo-city,Yamanashi,409-3898,Japan
Novartis Investigative Site
Recruiting
Yamagata,990 9585,Japan
Novartis Investigative Site
Recruiting
Kamogawa,Chiba,296-8602,Japan
Novartis Investigative Site
Recruiting
Fukui,910-8526,Japan
Novartis Investigative Site
Recruiting
Kashiwa,Chiba,277 8577,Japan
Novartis Investigative Site
Recruiting
Fukushima city,Fukushima,960 1295,Japan
Novartis Investigative Site
Recruiting
Kyoto,606 8507,Japan
Novartis Investigative Site
Recruiting
Gifu-city,Gifu,501-1194,Japan
Novartis Investigative Site
Recruiting
Osaka Sayama,Osaka,589 8511,Japan
Novartis Investigative Site
Recruiting
Hirosaki,Aomori,036 8563,Japan
Novartis Investigative Site
Recruiting
Saitama,330 8503,Japan
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.